HOST: CO- HOSTS: SHERATON WALL CENTRE HOTEL 1088 BURRARD STREET Vancouver, BC, Canada April 22 to 25, 2012 CO- SPONSORS: MAJOR INDUSTRY SPONSORS:

Similar documents
The use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART?

Background. Meeting Objective. Participants

Aids Fonds funding for programmes to prevent HIV drug resistance

S P. The Goals Model as a Tool for Allocating HIV/AIDS Resources & Strategic Planning

HPTN 073: Black MSM Open-Label PrEP Demonstration Project

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

HIV Guidelines. New Strategies.

The Botswana Combination Prevention Project (BCPP)

UNAIDS 2013 AIDS by the numbers

Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010

Will We End the HIV Epidemic?

How To Get Rid Of Hiv

Science addressing drugs and HIV: State of the Art. Vienna

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants

UPDATE UNAIDS 2016 DATE 2016

Implementation of a near real-time phylogenetic monitoring program for HIV transmission outbreaks

HIV New Diagnoses, Treatment and Care in the UK 2015 report

Q&A on methodology on HIV estimates

STOP HIV TB: Special Populations, The Vancouver Experience

Collaborative TB and HIV Services for Drug Users. Christian Gunneberg M.O. WHO

NICHD s Pediatric, Adolescent, & Maternal AIDS Branch

Cluster-randomized trials of combination prevention interventions. Victor DeGruttola.

SCIENCE AND TECHNOLOGY AS UGANDA AND THE SEARCH FOR AN AIDS VACCINE

HARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE

REPORTING CHANGES FOR 2014 NYSDOH AIDS INSTITUTE. Changes to Content and Priorities

50 years THE GAP REPORT 2014

HIV Services Quality Management Plan San José, CA (Santa Clara County) Transitional Grant Area. January 1 to December 31, 2012

countdown to zero Believe it. Do it.

WISCONSIN AIDS/HIV PROGRAM NOTES

Monitoring of HIV positive mothers and HIV exposed infants in context of Option B+ implementation

U.S. President s Malaria Initiative (PMI) Approach to Health Systems Strengthening

Case Finding for Hepatitis B and Hepatitis C

UNAIDS ISSUES BRIEF 2011 A NEW INVESTMENT FRAMEWORK FOR THE GLOBAL HIV RESPONSE

Hope in the midst of Despair! CHALLENGES AHEAD IN THE GLOBAL HIV EPIDEMIC

AGENDA Modeling the Spread and Control of Ebola in W. Africa Organizers: Mission: Motivation: Goals: Products: Major Sponsors:

Why Community Engagement?

Meeting Report Prevention and Treatment of HIV/AIDS among Drug Using Populations: A Global Perspective

Methodology Understanding the HIV estimates

HIV/AIDS IN SUB-SAHARAN AFRICA: THE GROWING EPIDEMIC?

Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries

International Service Program

Understanding the HIV Care Continuum

Moving Toward Reduced HIV Incidence: How the San Francisco Experience Can Inform National HIV/AIDS Strategy Implementation

Integrating surveillance and program intervention the promise of mhealth

Frequently Asked Questions (FAQs)

Dual elimination of mother-to-child transmission (MTCT) of HIV and syphilis

Perspective Implications of the Affordable Care Act for People With HIV Infection and the Ryan White HIV/AIDS Program: What Does the Future Hold?

children and THE GAP REPORT 2014

Session 4: The Drug Management Cycle: Selection. David Peters

Please describe the laboratory facilities available in your research institute, including the items listed below (if applicable):

The Global Epidemics of HIV among Men Who Have Sex with Men: Time for Action

BRIEF FOR PARLIAMENTARIANS ON HIV AND AIDS. Towards an HIV-free generation: Ending the vertical transmission of HIV

Rakai District HIV Education Project (RHEP)

Technical guidance note for Global Fund HIV proposals in Round 11

HIV/AIDS Prevention and Care

Current Sponsors NU

on the Job 24/7 Technical Conference & Trade Show September 20 th September 23 rd penticton trade & convention centre

UTAH DIVISION OF SUBSTANCE ABUSE AND MENTAL HEALTH SUBSTANCE USE DISORDER SERVICES MONITORING CHECKLIST (FY 2014) GENERAL PROGRAM REQUIREMENTS

Paediatric HIV Drug Resistance in African Settings

The Ryan White CARE Act 2000 Reauthorization

Alabama Community College Leadership Academy July 15 - July 18, Bryant Conference Center, Birmingham Room

Implementing a Comprehensive Student Success and Retention Plan [SSRP] for Higher education

A HISTORY OF THE HIV/AIDS EPIDEMIC WITH EMPHASIS ON AFRICA *

UNAIDS AND MÉDECINS SANS FRONTIÈRES 2015 REFERENCE COMMUNITY-BASED ANTI RETROVIRAL THERAPY DELIVERY EXPERIENCES OF MÉDECINS SANS FRONTIÈRES

Agenda. Wednesday, September :00 pm - 7:00 pm

Advanced Management Issues in HIV Medicine

ACB Management & Leadership Course 12 th 17th July 2015

Overview of CLIA-Waived Rapid HIV Tests and the HIV Rapid

HIV Continuum of Care Monitoring Framework 2014

Mark Dybul Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria. Eric Goosby Ambassador, United States Global AIDS Coordinator

Outpatient/Ambulatory Health Services

2014 Summer Conference Pittsburgh, PA July 25-27

Dave Burrows Director

Invitation to Host Academy Event

Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies

Page 1/.. USA / Canada - South Africa Schedule No. 4 / 2011-Jan-24

Using data and tools to inform resource allocation for the HIV response. Dr. Sarah Alkenbrack & Dr. Suneeta Sharma Futures Group

How To Help The Ghanian Hiv Recipe Cards

PEPFAR Blueprint: Creating an AIDS-free Generation

PEPFAR/CDC Site Monitoring System Goal and Objectives

Welcome RADM Frederick Lewis, USN (Ret) President, National Training and Simulation Association (NTSA)

ALL IN. #EndAdolescentAIDS

2016 MO/KS PRIMA Conference. got security? April 13-15, 2016 Tan-Tar-A Resort Osage Beach, Missouri

Discordant Couples and HIV Transmission

HIV AND ADOLESCENTS: HIV TESTING AND COUNSELLING, TREATMENT AND CARE FOR ADOLESCENTS LIVING WITH HIV SUMMARY OF KEY FEATURES AND RECOMMENDATIONS

The Basics of Drug Resistance:

Goal 6: Combat HIV/AIDS, malaria and other diseases

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM Alliance. Innovation PRELIMINARY. Management

THE GAP REPORT UNAIDS

Back by popular demand! For a fun and healthy start to your morning, please assemble in the Terrace Lobby.

Search and Rescue (SAR) Workshop III Improving SAR Coordination and Response in the Antarctic

Plan for AIDS Relief

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

The HIV/AIDS Epidemic in California s Latino Population

HIV Therapy Key Clinical Indicator (KCI)

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas

Mid-year population estimates. Embargoed until: 20 July :30

2015 Juvenile Justice Youth Summit The Time is Now: Creating Change with Young Emerging Leaders

The source documentation for the procedure will need to be identified for some items that are in the protocol, but not captured on the CRFs.

Dear Colleagues and Guests,

Transcription:

HOST: CO- HOSTS: CO- SPONSORS: SHERATON WALL CENTRE HOTEL 1088 BURRARD STREET Vancouver, BC, Canada April 22 to 25, 2012 OFFICE OF THE US GLOBAL AIDS COORDINATOR-THE UNITED STATES PRESIDENT S EMERGENCY PLAN FOR AIDS RELIEF LOCAL ACADEMIC PARTNERS: MAJOR INDUSTRY SPONSORS: INDUSTRY SUPPORTERS:

2 nd International HIV Workshop on Treatment as Prevention Sheraton Wall Centre Hotel 1088 Burrard Street Vancouver, BC, Canada April 22-25, 2012 April 22 th 2012- Day 1 (Opening) 15:00-17:00 Registration opens as early as 3:00 pm (Pavilion Foyer) 17:00 Opening Session (Pavilion Ballroom) 17:00-17:05 Welcome and Message from the Chair 17:05-17:25 Keynote Opening Address OGAC perspective on Treatment as Prevention Ambassador Eric Goosby, US Global AIDS Coordinator 17:20-19:00 Round Table: Setting the Stage Moderator: Jack Whitescarver (Office of AIDS Research) Panelists: 1) The state of the science Carl Dieffenbach (on behalf of NIAID) (20 min) 2) UNAIDS perspective Paul de Lay (on behalf of UNAIDS) (20 min) 3) WHO perspective Gottfried Hirnschall (on behalf of WHO) (20 min) 4) Hard to reach populations Nora Volkow (on behalf of NIDA) (20 min) 5) Mapping of TasP clinical trials Francois Dabis (on behalf of ANRS) (20 min) 19:00-19:30 19:30-20:40 Break Round Table: Perspective on TasP implementation Moderator: Elly Katabira

19:30-20:10 Panelists: Jim Shelton (15 min) Stephen Lewis (15 min) Moderated Discussion (10 min) 20:10-20:40 Open Microphone Discussion (30 min) 20:40 Day 1 concludes 2

April 23 rd 2012- Day 2 07:00-08:00 Breakfast Buffet (Pavilion Ballroom Foyer) 08:00-10:00 Review of scientific evidence and policy implications Moderator: Jean- Francois Delfraissy 08:00-09:00 Speakers: 1) HPTN052- Myron Cohen (15 min) 2) San Francisco Perspective - Grant Colfax (15 min) 3) China Perspective - Zunyou Wu (15 min) 4) An MSF Perspective on TasP: ongoing and planned projects in Africa Roger Teck (15 min) 09:00-10:00 Open Microphone Discussion (60 min) 10:00-10:30 10:30-12:00 Break Models, projections and cost- effectiveness analysis Moderator: Geoff Garnett 10:30-11:15 Speakers: 1) Models and projections I - Christophe Fraser (15 min) 2) Models and projections II Brian Williams (15 min) 3) Cost- effectiveness John Blandford (15 min) 11:15-12:00 12:00-13:30 Open Microphone Discussion (45 min) Poster Session & Lunch 13:30-15:30 Emerging insights from models, projections and cost- effectiveness analyses (Part 1) Moderator: Jean- Michel Molina 13:30-14:20 Speakers: 1) Systematic comparison of mathematical models of the potential impact of antiretroviral therapy in HIV incidence in South Africa Jeffrey Eaton (10 min) 3

2) Treatment as prevention for HIV in South Africa: different models show consistency in occurrence, but difference in timing of elimination and the overall impact of the intervention Jan Hontelez (10 min) 3) Comparison of universal access versus universal test and treat strategies for South Africa: an epidemiological and economic analysis Bradley Wagner (10 min) 4) Study protocol to evaluate the feasibility and cost- effectiveness of standard treatment vs enhanced service for early treatment initiation in roadside wellness centres attending to mobile populations along a trading corridor across South Africa, Zimbabwe and Zambia Gabriela Gomez (10 min) 5) Earlier initialization of highly active antiretroviral therapy is associated with log term survival and infections averted: findings from a deterministic model of a 10- year Ugandan cohort Fegal Mills (10 min) 14:20-14:35 Open Microphone Discussion (15 min) 14:35-15:30 Emerging insights from models, projections and cost- effectiveness analyses (Part 2) Moderator: Robert Eisinger 14:35-15:15 Speakers: 1) Modelling potential impact of expanding access to antiretroviral therapy and other prevention interventions on the concentrated HIV epidemic in Vietnam Masaya Kato (10 min) 2) Limited contribution to new infections from HIV- infected men who have sex with men on suppressive antiretroviral therapy Ard van Sighem (10 min) 3) The cost of scaling- up antiretroviral treatment: a costing study in 161 representative facilities in Ethiopia, Malawai, Rwanda, South Africa and Zambia Elya Tagar (10 min) 4) Modeling the impact of implementing a test- and- treat strategy within the US Criminal Justice System Viviane Dias Lima (10 min) 15:15-15:30 Open Microphone Discussion (15 min) 4

15:30-16:00 Break 16:00-18:15 Global policy (Part 1) Moderator: Bertrand Audoin 16:00-17:00 Speakers: 1) Global Guidelines - Reuben Granich (10 min) 2) When to Start: Investigator Perspective I Wafaa El- Sadr (10 min) 3) When to Start: Investigator Perspective II Diane Havlir (10 min) 4) Ind l v. public health benefit v. both Paul Kasonkomona (10 min) 16:40-17:00 Open Microphone Discussion (20 min) 17:00-18:15 Global policy (Part 2) Moderator: Paul de Lay 17:00-17:45 Speakers: 1) Tx 2.0: Where are we at? Mariangela Simao (15 min) 2) Treatment Optimization Stephen Becker (15 min) 3) Global Fund perspective TBC (15 min) 17:45-18:15 Open Microphone Discussion (30 min) 18:15 Day 2 concludes 19:00 22:00 Dinner Reception (Off site, TBC) 5

April 24 th 2012- Day 3 07:00-08:00 Breakfast Buffet (Pavilion Ballroom Foyer) 08:00-10:00 Challenges in the design and implementation of STTR initiatives Moderator: Chinazo Cunningham 08:00-09:30 Speakers: 1) PopART, a large cluster- randomised trial of combination prevention strategies: design considerations Christophe Fraser (15 min) 2) Pushing the boundaries of science and practice- MaxART: Maximizing ART for better health and zero new HIV infections in Swaziland Sithembile Dlamini (15 min) 3) Treatment- as- prevention in resource- limited settings: review of strengths, weaknesses, opportunities and threats in the context of Swaziland Charles Azih (15 min) 4) Challenges in the implementing HIV treatment as prevention in China Yan Zhao (15 min) 5) Integrating ART/PMTCT services into Maternal Neonatal & Child Health (MHCH) services to enhance test and treat for pregnant & lactating women (Option B+)- the Malawi experience Zengani Chirwa (15 min) 6) Assessing viral suppression amongst HIV patients accessing care in six cities using US HIV surveillance data for the TLC- Plus (HPTN 065) Study Deborah Donnell (15 min) 09:30-10:00 Open Microphone Discussion (30 min) 10:00-10:30 Break 10:30-12:00 Special Populations (4 orals) Moderator: Yvette Calderon 10:30-11:30 Speakers 1) Changing with the science: Anticipating new standard of care antiretroviral treatment recommendations for discordant couples in a home- based HIV testing cohort in Kenya Peter Cherutich (15 min) 2) The impact of incarceration on linkage to, retention in, and outcomes of care among low- income HIV- positive William Cunningham (15 min) 6

11:30-12:00 3) Update and results of opt- out and opt- in HIV testing for women detainees in Cook County Jail, Illinois Lawrence Ouellet (15 min) 4) CARE+ Corrections- Innovative use of technology in jails to support linkage and adherence to HIV care Curt Beckwith (15 min) Open Microphone Discussion (30 min) 12:00-13:30 Poster Session & Lunch 13:30-15:30 STTR Outcomes- initial results (6 orals) Moderator: Jacques Normand 13:30-15:00 Speakers: 1) Seek, test, treat and retain for PWIDs in East Africa: a stepped wedge evaluation of Kenya s needle program- Testing & Linkage to Care for PWIDs (TLC- PWID Kenya) Ann Kurth (15 min) 2) High testing uptake and linkages to HIV treatment through home based HIV counseling and testing and facilitated referral in Kabwohe, Uganda and KwaZulu- Natal (KZN), South Africa Ruanne Barnabas (15 min) 3) Scientific evidence and policy implication of treatment as prevention- China perspective Zunyou Wu (15 min) 4) Provider- initiated HIV testing on hospital admission: first pilot study in Argentina Maria Socias (15 min) 5) TLC- Plus (HPTN 065): design and implementation of a community- fucused HIV prevention study in the United States Wafaa El- Sadr (15 min) 6) Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and HIV new diagnoses- an update on the Treatment as Prevention experience in British Columbia Julio Montaner (15 min) 15:00-15:30 Open Microphone Discussion (30 min) 15:30-16:00 Break 16:00-17:10 Debate Implementation of TasP should await further Efficacy Trials 7

Moderator: Mark Harrington 16:00-16:40 Speakers: 1) For Jens Lundgren (15 min) 2) Against Joep Lange (15 min) 3) Rebuttals (5 min each) 16:40-17:10 Open Microphone Discussion (30 min) 17:10 Day 3 concludes 8

April 25 th 2012- Day 4 07:00-08:00 Breakfast Buffet (Pavilion Ballroom Foyer) 08:00-09:10 Debate TasP should not proceed without Viral Load Monitoring Moderator: Papa Salif Sow 08:00-08:40 Speakers: 1) For Vladimir Novitsky (15 min) 2) Against Jonathan Mermin (15 min) 3) Rebuttals (5 min each) 08:40-09:10 Open Microphone Discussion (30 min) 09:10-10:00 Break 10:00-11:30 Emerging Issues Moderator: Carlos del Rio 10:00-11:00 Speakers: 1) Cascade of care Peter Kilmore (15 min) 2) IAPAC guidelines Melanie Thompson (15 min) 3) Cell phone trials Richard Lester (15 min) 4) Elimination of Paediatric infection and TasP Craig McClure (15 min) 11:00-11:30 11:30-12:30 12:30-13:20 Open Microphone Discussion (30 min) Lunch Impact of antiretroviral therapy on TB control Moderator: Malcolm King 12:30-13:00 Speakers: 1) Stephen Lawn (20 min) 2) Commentary: Haileyesus Getahun (10 min) 9

13:00-13:20 Open Microphone Discussion (20 min) 13:20-14:50 Late Breaker Abstracts Session Moderator: Pedro Cahn Speakers: TBD 14:50-15:00 Closing remarks 10